#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

PEGASUS – Ticagrelor in secondary prevention on patients after a myocardial infarction


Authors: Jindřich Špinar 1,3;  Lenka Špinarová 2;  Jiří Vítovec 2
Authors‘ workplace: Interní kardiologická klinika LF MU a FN Brno, pracoviště Bohunice, přednosta prof. MUDr. Jindřich Špinar, CSc., FESC 1;  I. interní kardio-angiologická klinika LF MU a FN u sv. Anny Brno, přednostka prof. MUDr. Lenka Špinarová, CSc., FESC 2;  Mezinárodní centrum klinického výzkumu – FN u sv. Anny Brno 3
Published in: Vnitř Lék 2015; 61(6): 511-515
Category: Original Contributions

Overview

Background:
Ticagrelor is a P2Y12 receptor antagonist that has been shown to reduce ischemic events for up to a year after an acute coronary syndrome. The efficacy and safety of long-term ticagrelor therapy beyond 1 year after a myocardial infarction is unknown.

Methods:
We randomized 21,162 patients with a history of myocardial infarction within the prior 1–3 years in a double-blind 1 : 1 : 1 fashion to ticagrelor 90 mg twice daily, ticagrelor 60 mg twice daily, or placebo, all with low-dose aspirin, and followed them for a median of 33 months. The primary efficacy endpoint was the composite of cardiovascular death, myocardial infarction, or stroke. The primary safety endpoint was TIMI major bleeding.

Results:
Both doses of ticagrelor significantly reduced the primary combined efficacy endpoint compared to placebo with Kaplan-Meier rates at 3 years of 7.85 % with ticagrelor 90 mg, 7.77 % with ticagrelor 60 mg, and 9.04 % with placebo (HR for ticagrelor 90 mg vs placebo 0.85, 95% CI 0.75–0.96, p = 0.0080; HR for ticagrelor 60 mg vs placebo 0.84, 95% CI 0.74–0.95, p = 0.0043). Rates of TIMI major bleeding were higher with ticagrelor (2.60 % for 90 mg, 2.30 % for 60 mg and 1.06 % for placebo, p < 0.001 for each dose against placebo); the rates of intracranial hemorrhage or fatal bleeding were 0.63 %, 0.71 % and 0.60 % in the 3 arms, respectively.

Conclusions:
Treatment of patients more than 1 year after a myocardial infarction with ticagrelor reduces the risk of cardi­ovascular death, myocardial infarction, or stroke, and increases the risk of major bleeding.

Key words:
myocardial infarction – secondary prevention – ticagrelor


Sources

1. Scirica BM, Cannon CP, Emanuelsson H et al. The incidence or arrhythmias and clinical arrhythmias events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO trial. JACC 2010; 55(10s1): A108.E1006-A108.E1006. Dostupné z DOI: <http://dx.doi.org/1016/S0735–1097(10)61007–8>.

2. Špinar J, Vítovec J. Ticagrelor a studie PLATO. Kardiol Rev Int Med 2011; 13(4): 254–257.

3. Wallentin L, Becker RC, Budaj A et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361(11): 1045–1057.

4. Amsterdam EA, Wenger NK, Brindis RG et al. 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 130(25): 2354–2394.

5. Hamm CW, Bassand JP, Agewall S et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011; 32(23): 2999–3054.

6. O’Gara PT, Kushner FG, Ascheim DD et al. 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 127(4): e362-e425. Dostupné z DOI: <http://dx.doi.org/10.1161/CIR.0b013e3182742cf6>.

7. Steg PG, James SK, Atar D et al. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33(20): 2569–2619.

8. Bonaca MP, Bhatt DL, Cohen M et al. PEGASUS investigators. Long--term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015; 372(19):1791–1800. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa150087>.

9. Bonaca MP, Bhatt DL, Braunwald E et al. Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial. Am Heart J 2014; 167(4): 437–444.e5. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ahj.2013.12.020>.

10. Mehran R, Rao SV, Bhatt DL et al. Standardized Bleeding Definitions for Cardiovascular Clinical Trial. A Consensus Report From the Bleeding Academic Research Consortium. Circulation 2011; 123(23) 2736–2747.

11. Bhatt DL, Fox KA, Hacke W et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354(16): 1706–1717.

12. Bhatt DL, Flather MD, Hacke W et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol 2007; 49(19): 1982–1988.

13. Mauri L, Kereiakes DJ, Yeh RW et al. Twelve or 30 months of dual anti­platelet therapy after drug-eluting stents. N Engl J Med 2014; 371(23): 2155–2166.

14. Fihn SD, Gardin JM, Abrams J et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physi­cians, American Association for Thoracic Surgery, Preventive Cardio­vascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2012; 126(25): e354-e471. Dostupné z DOI: <http://dx.doi.org/10.1161/CIR.0b013e318277d6a0>.

15. Task Force Members, Montalescot G, Sechtem U et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013; 34(38): 2949–3003.

Labels
Diabetology Endocrinology Internal medicine

Article was published in

Internal Medicine

Issue 6

2015 Issue 6

Most read in this issue
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#